Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

6.42USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.42
Open
$6.42
Day's High
$6.48
Day's Low
$6.34
Volume
180,368
Avg. Vol
220,789
52-wk High
$7.73
52-wk Low
$3.21

SPPI.OQ

Chart for SPPI.OQ

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute... (more)

Overall

Beta: 1.46
Market Cap(Mil.): $515.22
Shares Outstanding(Mil.): 80.25
Dividend: --
Yield (%): --

Financials

  SPPI.OQ Industry Sector
P/E (TTM): -- 48.48 30.07
EPS (TTM): -0.93 -- --
ROI: -19.41 -2.48 13.05
ROE: -30.53 5.24 14.20

BRIEF-Spectrum Pharmaceuticals reports Q4 loss per share of $0.22

* Spectrum Pharmaceuticals reports fourth quarter 2016 and full year 2016 financial results and pipeline update

Mar 08 2017

Spectrum Pharma says FDA rejects its bladder cancer drug

Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker's bladder cancer treatment, apaziquone.

Nov 18 2016

UPDATE 1-Spectrum Pharma says U.S. FDA rejects its bladder cancer drug

Nov 18 Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker's bladder cancer treatment, apaziquone.

Nov 18 2016

BRIEF-Spectrum Pharma receives complete response letter from FDA for Qapzola

* Spectrum Pharmaceuticals Inc says on November 15, 2016, company met with FDA to discuss strategy for further development of Qapzola

Nov 18 2016

Spectrum Pharma says U.S. FDA rejects its bladder cancer drug

Nov 18 Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration rejected the drugmaker's bladder cancer treatment.

Nov 18 2016

BRIEF-Spectrum pharmaceuticals posts Q3 loss per share of $0.22

* Spectrum Pharmaceuticals Inc says total product sales were $30.3 million in Q3 of 2016

Nov 14 2016

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.26 -0.99
Pfizer Inc. (PFE.N) $34.47 +0.22
Novartis AG (NOVN.S) CHF73.40 -1.05
Merck & Co., Inc. (MRK.N) $63.50 -0.41
Roche Holding Ltd. (ROG.S) CHF250.20 +0.10
Roche Holding Ltd. (RO.S) CHF250.50 -0.25
Abbott Laboratories (ABT.N) $44.81 +0.01
Bayer AG (BAYGn.DE) €105.05 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.77 +0.05

Earnings vs. Estimates